Immune Stimulator May Enhance Targeted Therapy's Activity in Metastatic RCC
(MedPage Today) -- AUSTIN, Texas -- A dendritic-cell immune primer failed to meet survival endpoints in a randomized trial of high-risk synchronous metastatic renal cell carcinoma (mRCC) but nonetheless showed evidence of activity.
The 18-month...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news